RxDoctor Payments Data

Manish Parikh, MD

Internal Medicine · Brooklyn, NYNPI 1891882965

Payments from drug & device makers

$890,367in general payments, 2019–2025

Across 768 payments — averaging $1159.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$552K
  • Boston Scientific$129K
  • Medtronic$66K
  • Siemens Medical Solutions USA, Inc.$51K
  • Corindus Inc.$42K
  • Abbott$10K
  • plus $40K from 48 others

What the payments were for

  • Consulting fees$64,65527%
  • Speaking & faculty fees$99,16042%
  • Travel & lodging$29,72113%
  • Food & beverage$42,00518%
  • Education$3060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$890,367 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$239,357
Medicare patients
538
Services billed
2,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$255,290
EntrestoSacubitril/Valsartan189$238,076
JardianceEmpagliflozin139$167,174
Repatha SureclickEvolocumab112$89,360
FarxigaDapagliflozin Propanediol74$79,451
BrilintaTicagrelor67$63,382
Praluent PenAlirocumab63$44,714
JanuviaSitagliptin Phosphate17$26,657
VascepaIcosapent Ethyl29$19,940
XareltoRivaroxaban18$17,840
OzempicSemaglutide11$10,985
Rosuvastatin Calcium650$9,947
Metoprolol Succinate389$5,330
Ranolazine ErRanolazine59$4,982
ClopidogrelClopidogrel Bisulfate400$4,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$390$255,290204 claims
NovartisEntresto$602$238,076189 claims
Boehringer IngelheimJardiance$493$167,174139 claims
AstraZenecaFarxiga, Brilinta, Symbicort$616$145,592153 claims
Johnson & JohnsonXarelto$81$17,84018 claims
Novo NordiskOzempic$24$10,98511 claims
AbbVieSynthroid$146$67011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →